Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients

Michal Tkaczyszyn; Josep Comin-Colet; Adriaan A. Voors; Dirk J. van Veldhuisen; Cristina Enjuanes; Pedro Moliner; Marcin Drozd; Radoslaw Sierpinski; Piotr Rozentryt; Jolanta Nowak; Tomasz Suchocki; Waldemar Banasiak; Piotr Ponikowski; Peter van der Meer; Ewa A. Jankowska

doi:10.1002/ejhf.2253

Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients

Michal Tkaczyszyn^*, Josep Comin-Colet, Adriaan A. Voors, Dirk J. van Veldhuisen, Cristina Enjuanes, Pedro Moliner, Marcin Drozd, Radoslaw Sierpinski, Piotr Rozentryt, Jolanta Nowak, Tomasz Suchocki, Waldemar Banasiak, Piotr Ponikowski, Peter van der Meer, Ewa A. Jankowska

^*Corresponding author for this work

Cardiovascular Centre (CVC)

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

171 Downloads (Pure)

Abstract

Aims Abnormal endogenous erythropoietin (EPO) constitutes an important cause of anaemia in chronic diseases. We analysed the relationships between iron deficiency (ID) and the adequacy of endogenous EPO in anaemic heart failure (HF) patients, and the impact of abnormal EPO on 12-month mortality. Methods and results We investigated 435 anaemic HF patients (age: 74 +/- 10 years; males: 60%; New York Heart Association class I or II: 39%; left ventricular ejection fraction: 43 +/- 17%). Patients with EPO higher than expected for a given haemoglobin were considered EPO-resistant whereas those with EPO lower than expected - EPO-deficient. ID was defined as serum ferritin

Original language	English
Pages (from-to)	1677–1686
Number of pages	10
Journal	European Journal of Heart Failure
Volume	23
Issue number	10
Early online date	11-Jul-2021
DOIs	https://doi.org/10.1002/ejhf.2253
Publication status	Published - Oct-2021

Keywords

Heart failure
Iron deficiency
Anaemia
Erythropoietin
Mortality
BASE-LINE CHARACTERISTICS
CHRONIC KIDNEY-DISEASE
FERRIC CARBOXYMALTOSE
DARBEPOETIN ALPHA
MORTALITY
MECHANISMS
DESIGN

Access to Document

10.1002/ejhf.2253

Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patientsFinal publisher's version, 2.96 MBLicence: Taverne

Handle.net

Persistent link

Cite this

Tkaczyszyn, M., Comin-Colet, J., Voors, A. A., van Veldhuisen, D. J., Enjuanes, C., Moliner, P., Drozd, M., Sierpinski, R., Rozentryt, P., Nowak, J., Suchocki, T., Banasiak, W., Ponikowski, P., van der Meer, P., & Jankowska, E. A. (2021). Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. European Journal of Heart Failure, 23(10), 1677–1686. https://doi.org/10.1002/ejhf.2253

@article{5d19892bcee54918b7bec8a2a8814756,

title = "Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients",

abstract = "Aims Abnormal endogenous erythropoietin (EPO) constitutes an important cause of anaemia in chronic diseases. We analysed the relationships between iron deficiency (ID) and the adequacy of endogenous EPO in anaemic heart failure (HF) patients, and the impact of abnormal EPO on 12-month mortality. Methods and results We investigated 435 anaemic HF patients (age: 74 +/- 10 years; males: 60%; New York Heart Association class I or II: 39%; left ventricular ejection fraction: 43 +/- 17%). Patients with EPO higher than expected for a given haemoglobin were considered EPO-resistant whereas those with EPO lower than expected - EPO-deficient. ID was defined as serum ferritin",

keywords = "Heart failure, Iron deficiency, Anaemia, Erythropoietin, Mortality, BASE-LINE CHARACTERISTICS, CHRONIC KIDNEY-DISEASE, FERRIC CARBOXYMALTOSE, DARBEPOETIN ALPHA, MORTALITY, MECHANISMS, DESIGN",

author = "Michal Tkaczyszyn and Josep Comin-Colet and Voors, {Adriaan A.} and {van Veldhuisen}, {Dirk J.} and Cristina Enjuanes and Pedro Moliner and Marcin Drozd and Radoslaw Sierpinski and Piotr Rozentryt and Jolanta Nowak and Tomasz Suchocki and Waldemar Banasiak and Piotr Ponikowski and {van der Meer}, Peter and Jankowska, {Ewa A.}",

year = "2021",

month = oct,

doi = "10.1002/ejhf.2253",

language = "English",

volume = "23",

pages = "1677–1686",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Wiley",

number = "10",

}

Tkaczyszyn, M, Comin-Colet, J, Voors, AA , van Veldhuisen, DJ, Enjuanes, C, Moliner, P, Drozd, M, Sierpinski, R, Rozentryt, P, Nowak, J, Suchocki, T, Banasiak, W, Ponikowski, P, van der Meer, P & Jankowska, EA 2021, 'Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients', European Journal of Heart Failure, vol. 23, no. 10, pp. 1677–1686. https://doi.org/10.1002/ejhf.2253

TY - JOUR

T1 - Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients

AU - Tkaczyszyn, Michal

AU - Comin-Colet, Josep

AU - Voors, Adriaan A.

AU - van Veldhuisen, Dirk J.

AU - Enjuanes, Cristina

AU - Moliner, Pedro

AU - Drozd, Marcin

AU - Sierpinski, Radoslaw

AU - Rozentryt, Piotr

AU - Nowak, Jolanta

AU - Suchocki, Tomasz

AU - Banasiak, Waldemar

AU - Ponikowski, Piotr

AU - van der Meer, Peter

AU - Jankowska, Ewa A.

PY - 2021/10

Y1 - 2021/10

N2 - Aims Abnormal endogenous erythropoietin (EPO) constitutes an important cause of anaemia in chronic diseases. We analysed the relationships between iron deficiency (ID) and the adequacy of endogenous EPO in anaemic heart failure (HF) patients, and the impact of abnormal EPO on 12-month mortality. Methods and results We investigated 435 anaemic HF patients (age: 74 +/- 10 years; males: 60%; New York Heart Association class I or II: 39%; left ventricular ejection fraction: 43 +/- 17%). Patients with EPO higher than expected for a given haemoglobin were considered EPO-resistant whereas those with EPO lower than expected - EPO-deficient. ID was defined as serum ferritin

AB - Aims Abnormal endogenous erythropoietin (EPO) constitutes an important cause of anaemia in chronic diseases. We analysed the relationships between iron deficiency (ID) and the adequacy of endogenous EPO in anaemic heart failure (HF) patients, and the impact of abnormal EPO on 12-month mortality. Methods and results We investigated 435 anaemic HF patients (age: 74 +/- 10 years; males: 60%; New York Heart Association class I or II: 39%; left ventricular ejection fraction: 43 +/- 17%). Patients with EPO higher than expected for a given haemoglobin were considered EPO-resistant whereas those with EPO lower than expected - EPO-deficient. ID was defined as serum ferritin

KW - Heart failure

KW - Iron deficiency

KW - Anaemia

KW - Erythropoietin

KW - Mortality

KW - BASE-LINE CHARACTERISTICS

KW - CHRONIC KIDNEY-DISEASE

KW - FERRIC CARBOXYMALTOSE

KW - DARBEPOETIN ALPHA

KW - MORTALITY

KW - MECHANISMS

KW - DESIGN

U2 - 10.1002/ejhf.2253

DO - 10.1002/ejhf.2253

M3 - Article

SN - 1388-9842

VL - 23

SP - 1677

EP - 1686

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 10

ER -

Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this